|
 |
|
|
| |
Patent expiry opens huge potential for Biosimilars
 |
|
| Some of the biggest-selling biologics developed during the boom years in biotech of the 1980's, have lost patent protection in the US in 2007 or will shortly. This opens up huge potential market for biosimilars, if regulatory hurdles can be overcome |
|
 |
|
|
| |
| Biotech spreading across all regions in New Zealand
|
|
| Twenty-one percent of biotechnology organizations are active in the Auckland region, but biotechnology activity is spread evenly across the remainder of the country, according to the Statistics New Zealand
|
|
|
|
|
| |
|
|
| |
| US Biopharma R&D spending reaches $58.8 bn in 2007
|
|
| New statistics reveal that R&D investment in new medicines by the biopharmaceutical industry was $58.8 billion in 2007, according to a combined analysis conducted by Burrill & Company, and the Washington DC-based PhRMA |
|
|
|
|
| |
| Global RNAi market to grow at 25.6%
|
|
| The Global RNAi market is projected to grow at 25.6% compounded annually from 2005 to 2012. United States maintains its lead throughout. US and Europe are fore runners in RNAi based therapeutics |
|
|
|
|
| |
| Global stem cells market to reach $ 32.3 billion by 2012
|
|
| The global stem cells market is projected to reach about US$ 32.3 billion by 2012. Stem cell research has picked up pace like never before now. The technology is leading to a new kind of cell-based medicine that is regenerative in nature |
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| More |
